Literature DB >> 20089041

Functional and genetic characterization of the promoter region of apolipoprotein H (beta2-glycoprotein I).

Sangita Suresh1, F Yesim Demirci, Iliya Lefterov, Candace M Kammerer, Rosalind Ramsey-Goldman, Susan Manzi, M Ilyas Kamboh.   

Abstract

This study characterized the human apolipoprotein H [APOH; beta(2)-glycoprotein I (beta(2)GPI)] promoter and its variants by in vitro functional experiments and investigated their relationship with human plasma beta(2)GPI levels. We examined the individual effects of 12 APOH promoter single nucleotide polymorphisms in the 5' flanking region of APOH (approximately 1.4 kb) on luciferase activity in COS-1 cells and HepG2 cells and their impact on plasma beta(2)GPI levels in 799 American White people, the DNA binding properties of the APOH promoter using an electrophoretic mobility shift assay in HepG2 cells, the effects of serial deletion analysis of the APOH 5' flanking region in COS-1 and HepG2 cells and cross-species conservation of the APOH promoter sequence. The variant alleles of three single nucleotide polymorphisms (-1219G>A, -643T>C and -32C>A) showed significantly lower luciferase expression (51, 40 and 37%, respectively) as compared with the wild-type allele. The electrophoretic mobility shift assay demonstrated that these three variants specifically bind with protein(s) from HepG2 cell nuclear extracts. Three-site haplotype analysis (-1219G>A, -643T>C and -32C>A) revealed one haplotype carrying -32A (allele frequency = 0.075) to be significantly associated with decreased plasma beta(2)GPI levels (P < 0.001). Deletion analysis localized the core APOH promoter to approximately 160 bp upstream of ATG codon with the presence of critical cis-acting elements between -166 and -65. Cross-species conservation analysis of the APOH promoters of seven species indicated that basic promoter elements are highly conserved across species. In conclusion, we have characterized the functional promoter of APOH and identified functional variants that affect the transcriptional activity of the APOH promoter.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20089041      PMCID: PMC2860786          DOI: 10.1111/j.1742-4658.2009.07538.x

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  22 in total

1.  The binding of apolipoprotein H (beta2-Glycoprotein I) to lipoproteins.

Authors:  R Gambino; G Ruiu; G Pagano; M Cassader
Journal:  Prostaglandins Other Lipid Mediat       Date:  1999-07       Impact factor: 3.072

2.  Comprehensive analysis of transcriptional promoter structure and function in 1% of the human genome.

Authors:  Sara J Cooper; Nathan D Trinklein; Elizabeth D Anton; Loan Nguyen; Richard M Myers
Journal:  Genome Res       Date:  2005-12-12       Impact factor: 9.043

3.  Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor.

Authors:  M Galli; P Comfurius; C Maassen; H C Hemker; M H de Baets; P J van Breda-Vriesman; T Barbui; R F Zwaal; E M Bevers
Journal:  Lancet       Date:  1990-06-30       Impact factor: 79.321

4.  CCAAT displacement protein, a regulator of differentiation-specific gene expression, binds a negative regulatory element within the 5' end of the human papillomavirus type 6 long control region.

Authors:  S Pattison; D G Skalnik; A Roman
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

5.  Structure of the human beta2-glycoprotein I (apolipoprotein H) gene.

Authors:  H Okkels; T E Rasmussen; D K Sanghera; M I Kamboh; T Kristensen
Journal:  Eur J Biochem       Date:  1999-01

6.  Site-directed mutagenesis of recombinant human beta 2-glycoprotein I identifies a cluster of lysine residues that are critical for phospholipid binding and anti-cardiolipin antibody activity.

Authors:  Y Sheng; A Sali; H Herzog; J Lahnstein; S A Krilis
Journal:  J Immunol       Date:  1996-10-15       Impact factor: 5.422

Review 7.  Regulation of liver-specific gene expression.

Authors:  C Noda; A Ichihara
Journal:  Cell Struct Funct       Date:  1993-08       Impact factor: 2.212

8.  Identification of structural mutations in the fifth domain of apolipoprotein H (beta 2-glycoprotein I) which affect phospholipid binding.

Authors:  D K Sanghera; D R Wagenknecht; J A McIntyre; M I Kamboh
Journal:  Hum Mol Genet       Date:  1997-02       Impact factor: 6.150

9.  Liver is not the unique site of synthesis of beta 2-glycoprotein I (apolipoprotein H): evidence for an intestinal localization.

Authors:  M Averna; G Paravizzini; G Marino; E Lanteri; G Cavera; C M Barbagallo; S Petralia; S Cavallaro; G Magro; S Grasso; A Notarbartolo; S Travali
Journal:  Int J Clin Lab Res       Date:  1997

10.  Genetic variation in the apolipoprotein H (beta2-glycoprotein I) gene affects plasma apolipoprotein H concentrations.

Authors:  H Mehdi; C E Aston; D K Sanghera; R F Hamman; M I Kamboh
Journal:  Hum Genet       Date:  1999 Jul-Aug       Impact factor: 4.132

View more
  2 in total

1.  Association of the Trp316Ser variant (rs1801690) near the apolipoprotein H (β2-glycoprotein-I) gene and serum lipid levels.

Authors:  Tao Guo; Rui-Xing Yin; Hui Li; Yi-Ming Wang; Jin-Zhen Wu; De-Zhai Yang
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

2.  Genome-wide significant results identified for plasma apolipoprotein H levels in middle-aged and older adults.

Authors:  Karen A Mather; Anbupalam Thalamuthu; Christopher Oldmeadow; Fei Song; Nicola J Armstrong; Anne Poljak; Elizabeth G Holliday; Mark McEvoy; John B Kwok; Amelia A Assareh; Simone Reppermund; Nicole A Kochan; Teresa Lee; David Ames; Margaret J Wright; Julian N Trollor; Peter W Schofield; Henry Brodaty; Rodney J Scott; Peter R Schofield; John R Attia; Perminder S Sachdev
Journal:  Sci Rep       Date:  2016-03-31       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.